Clinical Edge Journal Scan

Cumulative social risk linked to reduced receipt of chemotherapy in patients with advanced CRC


 

Key clinical point: Assessment of cumulative social risk can help identify patients with advanced colorectal cancer (CRC) at higher risk of omitting chemotherapy for nonclinical reasons. Systematic assessment of patients for social risk and a more holistic support program may encourage such patients to undergo their recommended chemotherapy regimen.

Major finding: Compared with participants with 0 social risk factors, those with 3 (odds ratio [OR], 0.48; P = .02) or more (6 or more; OR, 0.22; P = .001) risk factors were significantly less likely to receive planned chemotherapy. Those who reported 2 (OR, 3.05; P = .007) or more (6 or more sources; OR, 5.95; P less than .001) sources of social support were more likely to receive chemotherapy than participants with no social support.

Study details: Findings are from a cross-sectional, population-based survey of 1,087 adults diagnosed with stage III CRC.

Disclosures: The study was supported by a research scholar grant from the American Cancer Society. Dr. Abrahamse, Dr. Kato, and Dr. Ward reported receiving grants from various sources.

Source: Davis RE et al. JAMA Netw Open. 2021 Jun 1. doi: 10.1001/jamanetworkopen.2021.13533 .

Recommended Reading

Cumulative inflammatory burden predicts cancer risk in ulcerative colitis
MDedge Hematology and Oncology
FDA approves frontline immunotherapy for gastric cancers
MDedge Hematology and Oncology
First AI device for colonoscopy: Extra set of expert ‘eyes’
MDedge Hematology and Oncology
Does surgery for colorectal liver metastases release tumor cells?
MDedge Hematology and Oncology
CRC screening guidelines: 45 is the new 50, and 85 is the new 75
MDedge Hematology and Oncology
NPs and PAs performing colonoscopies: Why not?
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: Colorectal Cancer July 2021
MDedge Hematology and Oncology
Continuation of screening endoscopy beyond age 75 prevents CRC incidence and death
MDedge Hematology and Oncology
Perioperative systemic therapy feasible and safe in patients with resectable colorectal peritoneal metastases
MDedge Hematology and Oncology
HLX04, an alternative biosimilar to bevacizumab for refractory/metastatic colorectal cancer
MDedge Hematology and Oncology